By use of a computer-generated randomisation sequence , we randomly allocated patients ( 2:2:1:1 ; block size of six ; no stratification ) to drisapersen 6 mg/kg or placebo , each given subcutaneously and either continuously ( once weekly ) or intermittently ( nine doses over 10 weeks ) .